Skip to main content

Early-Stage Cancer Diagnoses Decreased During First Year of COVID-19

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Aug. 3, 2023 -- The number of cancer diagnoses decreased following COVID-19 emergence in March 2020, with the largest decrease seen for stage I disease, according to a study published in the August issue of The Lancet Oncology.

Xuesong Han, Ph.D., from the American Cancer Society in Atlanta, and colleagues examined nationwide changes in adult cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic by cancer type and sociodemographic factors in a cross-sectional study. Adults aged 18 years and older newly diagnosed in 2018 to 2020 were identified from the National Cancer Database, with a total of 2,404,050 adults newly diagnosed with cancer (830,528 in 2018; 849,290 in 2019; and 724,232 in 2020).

The researchers found that for all stages, the number of diagnoses decreased substantially following COVID-19 emergence in March 2020. By the end of 2020, monthly counts returned to near prepandemic levels. The largest decrease was seen for stage I, resulting in higher odds of late-stage diagnoses in 2020 compared with 2019 (adjusted odds ratios, 0.946 for stage I and 1.074 for stage IV). In most cancer types and sociodemographic groups, the pattern was observed, and it was most prominent among underserved individuals, including Hispanics, Asian American and Pacific Islanders, the uninsured, and those living in the most socioeconomically deprived areas.

"These findings likely reflect the time when individuals sought care or screening during the pandemic rather than a stage shift in cancer progression," Han said in a statement. "More ongoing cancer surveillance with longer-term data is warranted to better understand the full impact of the COVID-19 pandemic."

Two authors disclosed ties to AstraZeneca; one author serves on the Flatiron Health Equity Advisory Board.

Abstract/Full Text

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Further Support and Information on COVID-19

Read this next

ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy

FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...

No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes

MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...

Recommendations Issued for Palliative RT for Symptomatic Bone Mets

THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.